指南与共识类风湿关节炎

今日或明日如何治疗未分化关节炎?基于当前证据对治疗推荐意见的考量

How to treat undifferentiated arthritis today or tomorrow? A consideration of treatment recommendations in light of current evidence.
指南 / 共识 · Ann Rheum Dis · 2025-02-15

未分化关节炎(UA)是临床表现明显但无明确诊断或分类的炎性关节炎,当前UA治疗推荐多借鉴类风湿关节炎(RA)推荐,其依据是2000年代前2010年RA分类标准产生的研究,且基于UA为RA早期阶段的理念。本文基于2010-UA文献逐条评估四项外推条件,发现2010-UA较1987-UA初始表现及疾病结局更轻,当今UA人群>95%抗瓜氨酸化蛋白抗体阴性、多表现为单关节炎或少关节炎、常自发缓解、罕进展为RA,作者认为2010-UA是早期关节炎谱中独立患者群体,需进一步研究后推荐意见可能需更新。

要点

  • 当前UA治疗推荐与RA推荐大体相似,依据是UA为RA早期阶段的理念及2010年RA分类标准产生前的研究。
  • 针对「2010-UA」尚无随机安慰剂对照试验,推荐是否仍有效存疑。
  • 当今UA人群>95%抗瓜氨酸化蛋白抗体阴性,多表现为单关节炎或少关节炎,常自发缓解,罕进展为RA。

核心结论

  • 2010-UA较1987-UA初始表现及疾病结局更轻,当今UA人群>95%抗瓜氨酸化蛋白抗体阴性、多表现为单关节炎或少关节炎、常自发缓解、罕进展为RA。
  • 作者认为2010-UA是早期关节炎谱中独立患者群体,需进一步研究,之后推荐意见可能需更新。

研究设计与样本

  • 本文为基于2010-UA文献的考量性综述,逐条评估将1987-UA治疗推荐外推至2010-UA的四项条件。

主要发现

  • 当前UA治疗推荐与RA推荐大体相似,基于UA为RA早期阶段的理念及2010年RA分类标准产生前的研究。
  • 针对「2010-UA」尚无随机安慰剂对照试验。
  • 2010-UA较1987-UA初始表现及疾病结局更轻。
  • 当今UA人群>95%抗瓜氨酸化蛋白抗体阴性,多表现为单关节炎或少关节炎,常自发缓解,罕进展为RA。

关键数值与推荐

  • 将1987-UA治疗推荐外推至2010-UA需满足四项条件:基本患者特征相同、长期结局相似、预后因素大体相同、有随机安慰剂对照试验以外研究提示DMARD治疗在2010-UA有效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 针对「2010-UA」尚无随机安慰剂对照试验。
  • 作者认为2010-UA需进一步研究,之后推荐意见可能需更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with undifferentiated arthritis (UA) have clinically apparent inflammatory arthritis but no evident diagnosis or classification. Considering UA as a definition 'per exclusionem' implies that the population designated by this term is affected by changes in the way other diseases, eg, rheumatoid arthritis (RA), are classified or diagnosed. Current treatment recommendations for UA are largely similar to recommendations for RA. The recommendations are based on the idea that UA is an early stage of RA and on literature generated in the 2000s before the development of the 2010 classification criteria for RA. However, conventional UA (so-called '1987-UA') is presumably different than contemporary UA ('2010-UA'). Strikingly, there are no randomised placebo-controlled trials done on '2010-UA,' and this poses questions on whether the recommendations for UA are still valid. In this absence, we assume that treatment recommendations from '1987-UA' can be extrapolated to '2010-UA' if (1) essential patient characteristics are the same, (2) long-term outcomes are similar, (3) prognostic factors are largely the same, and (4) there are indications from research other than placebo-controlled randomized clinical trials (RCTs) that disease modifying antirheumatic drug (DMARD) treatment in 2010-UA is effective. We evaluate these requirements one by one based on the literature on 2010-UA. This reveals that 2010-UA is milder in initial presentation and disease outcomes than 1987-UA. Today's UA population is >95% anticitrullinated protein antibody-negative, presents with mono- or oligoarthritis, frequently achieves spontaneous remission, and rarely progresses to RA. We suggest that 2010-UA is a distinct patient group within the early arthritis spectrum, requiring additional research, after which recommendations may need to be updated.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van der Helm-van Mil AHM, Aletaha D. How to treat undifferentiated arthritis today or tomorrow? A consideration of treatment recommendations in light of current evidence. Ann Rheum Dis. 2025. PMID: 39956701. doi:10.1016/j.ard.2025.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。